Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes by Angelis, P M De et al.
The molecular genetic model for colorectal carcinogenesis empha-
sizes the accumulation of, and sequence of, genetic aberrations in
the development of sporadic colorectal carcinomas from
adenomas (Fearon and Vogelstein, 1990). The aberrations identi-
fied thus far include deletions and/or point mutations of several
important tumour suppressor genes such as APC, DCC and TP53
(Bodmer et al, 1987; Fearon et al, 1987; Solomon et al, 1987;
Vogelstein et al, 1988; Muleris et al, 1990; Powell et al, 1992;
Meling et al, 1993; Miyaki et al, 1994) and mutations of onco-
genes such as K-ras (Bos, 1989; Giaretti et al, 1996). Although
genetic instability resulting from mutations may occur in all
colorectal carcinomas, it seems unlikely that all have the same
genetic evolutionary pattern, since there exist distinct differences
in the histopathological features, distribution, clinical behavior
and molecular characteristics of precursor lesions and invasive
tumours (reviewed in Ilyas and Tomlinson, 1996; Houlston and
Tomlinson, 1997).
Colorectal carcinomas can be grouped into two ploidy classes
by flow cytometry measurements of tumour DNA content. DNA
aneuploid tumours, including hyperdiploid, highly aneuploid and
tetraploid tumours, have a stem line with abnormal DNA content,
and DNA diploid tumours have normal cellular DNA content
(Hiddemann et al, 1984). The calculated tumour DNA index is the
ratio of G0/G1 peak channels of the tumour cells to normal (refer-
ence) cells and can be assumed to reflect the tumour karyotype,
since there is good agreement between DNA index and chromo-
some number as determined by karyotypic analysis in human
tumours and tumour cell lines (Tribukait et al, 1986; Bigner et al,
1987). Approximately 60% of all colorectal adenocarcinomas are
DNA aneuploid, which often results in a poorer prognosis for the
patient than if they are DNA diploid (Rognum et al, 1991; Bauer et
al, 1993).
Flow cytometric measurements of tumour DNA content cannot
elucidate the specific numerical and structural aberrations that
occur in tumours. A technique that allows simultaneous screening
of the entire tumour genome for chromosomal gains and losses
was developed in 1992 (Kallioniemi et al, 1992) and called
comparative genomic hybridization (CGH). CGH allows detection
of amplified and/or deleted chromosomal regions in tumours
(corresponding to putative oncogenes and/or tumour suppressor
genes respectively) by mapping their locations on normal
metaphase chromosomes, and has been used to screen for amplifi-
cations and deletions in several types of human neoplastic disease
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(Kallioniemi et al, 1992; Cher et al, 1994; Kallioniemi et al, 1995;
Arnold et al, 1996; Korn et al, 1996; Heselmeyer et al, 1997;
Tirkkonen et al, 1998). Recent CGH investigations of colorectal
cancer (Ried et al, 1996; Nakao et al, 1998) have used indirect
fluorescence methods to analyse relatively small series of primary
colorectal carcinomas (16 and nine tumours respectively).
A characterization of the possible cytogenetic differences
between DNA aneuploid and diploid tumours could result in a
better understanding of differences in their respective biologies/
behaviours. We screened a series of 45 sporadic unfixed colorectal
carcinomas for chromosomal aberrations using a direct CGH
method, which uses tumour and reference DNA probes that are
directly conjugated to specific fluorochromes. Direct CGH
improves the accuracy and reliability of CGH analysis compared to
earlier, indirect methods (Karhu et al, 1997). DNA aneuploid and
diploid colorectal tumours were analysed for possible differences
Table 1 Chromosomal gains and losses detected by CGH in 45 colorectal tumours
Tumour Gender Dukes’ DI Gains Losses
stage
90–8 M C 1.00 20q
90–10 F B 1.00
92–4 M B 1.00
93–3 F B 1.00 8pter-q13 4pter-q26, 6q16.2–23
93–11 F B 1.00
94–3 M B 1.00 X 9p13–21
94–5 F B 1.00 7, 8q21.2-ter, 13q, 17q21.3-ter, 20 3p, 4p, 5qcen-21, 8p21.1-ter, 15qcen-22.2, 17p13, 18q22-ter
94–14 M B 1.00 20q
94–17 M B 1.00 20 8, 18
94–19 F D 1.00 X
94–22 M C 1.00 X
94–25 F B 1.00
94–26 F B 1.00 19p 4qcen-24
94–27 M B 1.00 7p, 13q, 19, 20 1pcen-32.2, 4q22-ter, 18qcen-21
C896 F C 1.10 8q, 17q, 20q 1p13.3–31, 1q24–32.1, 2p12–23, 2q21.2–33, 4, 5, 6qcen-25.1,
8p21.3-ter, 18, Xp21.3-ter
92–9 F B 1.15 Xq 9p
92–29 F B 1.16 8q13–21, 8q24, 16p, 19, 20q 1p21–31, 4pcen-14, 5q23–31
94–23 F B 1.20 20q 5q14–21, X
C1340 M D 1.20 7p, 8q, 13q, 17q, 20q, Xq 1q24–31, 4, 5q14-ter, 6qcen-22, 8p, 9p21-ter, 10qcen-25, 17p13-ter, 18
C1402 M C 1.20 7, 8p21.3-ter, 16q21-ter, 19, 20q 1p31.1, 2q24.2–31, 4q, 10p 12-ter, 18
92–6 F D 1.31 7, 9q, 13q, 20 1pcen-22, 4, 5q31.3-ter, 9p23-ter
92–2 M D 1.37 7, 8q, 11p14-ter, 13q, 17q21.2-ter, 20, Xq 1, 4, 5q14-ter, 8p, 9q, 10, 12q, 14q, 17p12-ter, 18q, 21q, 22q
93–6 F C 1.42 13qcen-12, 16p, 20q, X 4, 6q15–23, 9p, 10q, 11q13.5-ter, 18q, 20p12-ter
93–8 M C 1.49 7, 13q, 20q 1p21–32, 2, 4, 6qcen-23, 9, 11q14.2-ter, 14q13-ter, 15q24-ter, 18,
20p13, X
90–17 M B 1.50 7, 8q, 9q, 13qcen-14.2, 20q13, Xpter-q21.2 4, 5q, 6qcen-25, 8p21.1-ter, 13q21-ter, 15q, 16q, 18q
94–12 M C 1.51 1q23-ter, 3, 4p, 5p, 7, 8q, 11q14-ter, 13q,  15q, 17p, 18qcen-12.3
19q, 20, 21q, 22q, X
93–9 M B 1.54 7, 8q, 11p15.1-ter, 20 1pcen-34, 2p13-ter, 3p23-ter, 4q31.2-ter, 5q13–31.2, 8p21.1-ter, 10p,
12p12-ter, 15q, 18q
92–26 F C 1.57 5p, 8q24, 13q32-ter 6q21–23, 14q, 15qcen-22, 17pcen-12, 18q, 21, 22q12.3-ter
94–15 M C 1.58 5p, 9, 20q13 15q, 17p, 18q, 21q
94–13 M B 1.59 13q32-ter, X
92–8 M D 1.60 2q22-ter, 7, 12q, 13q, 16q22-ter,  1p22-ter, 4, 8p, 11q21-ter, 15q15-ter, 17p12-ter, 18
17q21.3-ter, 20q, X
94–28 M B 1.63 6p23-ter, 7p, 13q, 16p, 20, X 1p, 4, 5qcen-32, 15q, 17p, 18q
93–2 M C 1.66 1q, 6pcen-22, 16p, 20, Xqcen-21, Xq25–26 1p21–22.3, 4q24–31.1, 15qcen-22, 18
92–30 M B 1.67 8q23-ter, 13q, 20, X
94–18 M C 1.69 5p, 6p21.2-ter, 7p, 8q21.1-ter, 11q13–22.1,  3p, 4, 5q11.2–32.3, 8pter-21.2, 18, 19pter-q13.1
16q22-ter
92–1 M C 1.70 7p15-ter, 8q24, 11qcen-14.3, 12, 13q,  3p, 6q, 8p22-ter, 18q
17q22-ter, 20, Xq
94–24 M D 1.70 X 9p23-ter
94–21 M D 1.74 20q13
95–2 M B 1.75 6p21.1-ter, 6q25-ter, 8q23-ter, 9q33-ter,  10, 17pter-q21, 18
13q, 20q
94–9 M B 1.78 13q, 19q, 20 8p, 18qcen-21
93–5 M B 1.83 4p14-ter, 5p14-ter, 8q, 20q
95–1 M B 1.91 8q, 13q, 20q 8p21.1-ter, 15q, 17p, 18, 20p12-ter
94–8 M C 1.94 19p13.2
94–10 F D 1.97 13q32-ter, 20q
94–33 M 2.22,1.61 5p13.2–14, 6p21.2-ter, 7, 8q, 13q, 17q,  1p34.1-q41, 3, 4p, 5qcen-33, 6q14–25.2, 9q, 10, 12. 15q, 18q, 21q
20, X, Xp
High-level gains (ratios > 1.5) are typed in bold print. M = male; F = female.in the type and frequency of recurrent chromosomal aberrations.
We investigated possible associations of chromosomal aberrations
with specific genotypes and phenotypes measured for this tumour
set, and with several clinicopathological parameters.
MATERIALS AND METHODS
Tumour material
Forty-five colorectal carcinomas that had been surgically-removed
and immediately frozen at –80°C were used for CGH analysis. The
tumours were previously graded according to Dukes’ stage (23
were Duke’s B, 13 were Dukes’ C and eight were Dukes’ D; one
tumour was not classified). Thirty tumours were obtained from
male patients and 15 tumours from female patients. Gender and
Dukes’s stage information for this tumour group are presented in
Table 1.
Most of the tumours used in this study were previously analysed
for DNA content (De Angelis et al, 1993, 1995) using flow cytom-
etry and the method of Vindeløv et al (1983) (DNA indices for
each tumour are listed in Table 1). CGH analysis was done using
DNA extracted directly from tumour samples re-analysed for
DNA content on a FACSVantage laser flow cytometer (BDIS, San
Jose, CA, USA) (21 cases) or using DNA extracted from fresh
tumour tissue upon receipt of the tumours (24 cases).
Criteria for inclusion of tumours in CGH study
A recent study (Kallioniemi et al, 1994) has demonstrated the
importance of having at least 50% tumour cells in samples
analysed by CGH in order to ensure optimal detection of amplifi-
cations and deletions. In our study, DNA aneuploid tumour
samples for CGH analysis generally contained more than 60%
tumour cells (median 68%) as determined by DNA flow cytom-
etry. This value was not possible to determine for DNA diploid
tumours by flow cytometry. However, since estimates of percent-
ages of non-tumour epithelial cells and infiltrating leucocytes from
histological sections of DNA aneuploid and diploid tumours were
consistent with the percentages quantitated for the diploid compo-
nent in aneuploid tumours by flow cytometry, it was reasonable to
assume that the majority of diploid tumours also contained more
than 60% tumour cells.
Comparative genomic hybridization
DNA extraction
The preparation of genomic DNA from colorectal tumour samples
was done using a standard protocol for DNA isolation. Slices of
tumour tissue were cut up into small bits in 2 ml proteinase-K (PK)
digestion buffer (100 mM sodium chloride, 10 mM Tris-HCl pH 8.0,
25 mM EDTA pH 8.0, 0.5% sodium dodecyl sulphate (SDS), to
which PK was added when ready to use; 50 ml of a 20 mg ml–1 PK
stock solution was added to 10 ml buffer). Alternatively, tumour
cell suspensions stained for DNA flow cytometry were spun down
to remove the propidium iodine (PI) staining solution, the pellets
vortexed and resuspended in 2 ml PK digestion buffer. In both
cases, samples were allowed to incubate at 50°C overnight with
shaking. When nearly all of the cellular protein was degraded,
the digest was deproteinized by successive extractions with
phenol:chloroform:isoamyl alcohol 49.5:49.5:1 (Fluka, Buchs,
Switzerland). The DNA was recovered by ethanol precipitation,
dried and resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA
pH 8.0). Tumour DNA concentrations were determined by
measuring the fluorescence of Hoechst 33258-stained samples in a
fluorometer.
Nick-translation and hybridization
CGH was done using directly fluorochrome-conjugated DNAs, as
described previously (Kallioniemi et al, 1994) with minor modifica-
tions. Briefly, 1 mg genomic DNA was nick-translated with
1 nmol each of dATP, dCTP, dGTP (Gibco BRL, Gaithersburg, MD,
USA), and either Texas red-5-dUTP (DuPont NEN, Boston, MA,
USA) for normal reference DNA or -fluoroscein isothiocyanate
(FITC)-12-dUTP (DuPont NEN, Boston, MA, USA) for tumour
DNA, at 15°C for 45–90 min with 9 units of DNA polymerase I
(Gibco BRL, Gaithersburg, MD, USA and Promega, Madison, WI,
USA) and 0.03 units DNase I (Gibco BRL). The reaction was
stopped by heating at 70°C for 10 min. Probe fragment sizes were
generally distributed in the range of 800–3000 basepairs, if not then
the nick-translation was repeated with an adjusted reaction time.
The metaphase preparations for CGH hybridization were
prepared according to routine procedures from PHA-stimulated,
methotrexate-synchronized, peripheral blood lymphocytes. The
latter were dropped onto slides in a room with 60–65% relative
humidity and stored at –20°C in 100% ethanol or at 0°C in a
nitrogen-flushed dessicator. Before hybridization, the slides were
denatured for 3 min at 74°C in 70% formamide, 2 ´ saline–sodium
citrate (SSC) (pH 7.0), dehydrated in a sequence of 70%, 85% and
100% ethanol, incubated in a PK solution (0.1 mg ml–1 in 20 mM
Tris-HCl per 2 mM calcium chloride, pH 7.5) for 7.5 min at room
temperature, dehydrated in the same alcohol series, air-dried and
placed in a 37°C warm room. The hybridization mixture was
prepared by mixing 200–400 ng FITC-labelled tumour DNA,
200–400 ng Texas red-labelled normal DNA, 20 mg Cot-1 DNA
(Gibco BRL), 1/10 vol, 3 M sodium acetate and 2 vol, 100%
ethanol. Tumours from males were always hybridized with male
reference DNA, and tumours from females with female reference
DNA. The probe mixture was precipitated by centrifugation at
14 000 rpm for 30 min at room temperature, the supernatant
decanted, and the pellets air-dried. DNA was then dissolved in
10 ml hybridization buffer (50% formamide, 10% dextran sulfate,
2 ´ SSC, pH 7.0), denatured at 70°C for 5 min and then placed in a
37°C warm room. The hybridization mixture was applied to the
slide spot, the area covered by a coverslip and sealed with rubber
cement. The hybridized spreads were incubated at 37°C in a
humidified chamber for 2–3 days. After hybridization, the slides
were subjected to three 10-min washes in 50% formamide per 2 ´
SSC (pH 7.0) at 45°C, followed by two 10-min washes in 2 ´ SSC
at 45°C, one 10-min wash in 2 ´ SSC per 0.1% Triton X-100 at
room temperature and, finally, one wash in distilled water. They
were then dehydrated in 70%, 85%, 100% ethanol, air-dried
and mounted using an anti-fade solution, Vectashield (Vector
Laboratories, Burlingame, CA, USA), containing 0.2 mM DAPI.
Microscopy and data analysis
DAPI fluorescence and probe signals were observed sequentially
with a Zeiss Axioplan fluorescence microscope equipped with a
triple-pass emission filter (blue, green and red), a corresponding
beam splitter and separate excitation filters (UV, 470–490 nm,
578 nm). All filters (‘Pinkel 1’ filter set) were obtained from
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Chroma (Brattleboro, UK). Images from 7–9 metaphases were
captured and digitized in a cooled 16-bit black/white CCD camera
(Astromed, Cambridge, UK).
Segmentation and calculation of ratio profiles were performed
with CGH software (kindly provided by Damir Sudar), running
under the ‘Scilimage’ image analysis program (TNO, Delft, The
Netherlands) with Resource for Molecular Cytogenetic extensions
(from Damir Sudar and Joe Gray, UCSF). This program segments
metaphase chromosomes on the basis of the sum of the DAPI and
Texas red images, subtracts background locally for each chromo-
some in the FITC and Texas red images, and calculates the inten-
sity along each chromosome by integrating perpendicularly to the
median axis. The total FITC and Texas red intensities for all chro-
mosomes are used to normalize the intensities before calculation
of the ratio between FITC and Texas red as a function of fractional
length.
Normal reference DNA was also FITC-labelled and hybridized
to normal reference DNA which had been TR-labelled in order to
check that the green to red fluorescence intensity profiles for each
chromosome were close to 1.0.
Criteria for hybridizations and for scoring tumour
chromosomal aberrations
Hybridization quality was assessed microscopically, and was
generally considered to be acceptable if there was uniform strong
hybridization over all metaphase spreads and if each spread gener-
ated consistent fluorescent intensity profiles. Hybridizations that
resulted in low FITC or Texas red chromosomal fluorescence
(signal to background ratio < 2), ‘grainy’ chromosome appearance,
or poor to no blocking of the labelled probes to the centromere
regions and the p-arms of acrocentric chromosomes, were
repeated. Approximately 50% of the tumours were hybridized 2–3
times to obtain acceptable results.
The average and standard deviation of several (> 3) profiles of
each chromosome were calculated, and more profiles were added
until the averaged profile and standard deviation did not change
after the addition of a new one. When using these criteria, ratios
less than 0.85 and greater than 1.15 were never observed in normal
versus normal hybridizations. Amplifications and deletions were
therefore scored if the ratio was above 1.15 and below 0.85 respec-
tively. These cut-off values are generally used for CGH analysis
(Kallioniemi et al, 1994; Tirkkonen et al, 1998). Additionally,
it was a requirement that the mean ratio plus one standard devia-
tion did not exceed 1.0 for the deletions, and that the mean ratio
minus one standard deviation was not below 1.0 for the amplifica-
tions. These last precautions ensured that inconsistent rises or
declines in the ratio of single profiles (e.g. at the telomeres) were
not scored as aberrations. Chromosome Y hybridization was
generally weak, and possible aberrations on this chromosome were
not scored. Apparent aberrations on the p-arms of acrocentric
chromosomes and in centromere regions were not scored. It is
important to note that, although the ratios may fluctuate in these
regions, the normalization, and thereby the ratios in other ‘unique’
regions of the genome, are not much affected because the
integrated intensities, rather than the integrated ratio, are used for
normalization.
Determination of tumour genotypes and phenotypes
TP53 genotype/phenotypes were determined previously for this
tumour set (De Angelis et al, 1993, 1995, 1998) using the tech-
niques of constant denaturant gel electrophoresis (CDGE), DNA
sequencing and immunoblotting. Forty tumours were also
analysed for mutations in codons 12 and 13 of the K-ras gene
using enriched polymerase chain reaction (PCR) techniques,
restriction fragment length polymorphism analysis and direct
sequencing as described previously (Andersen et al, 1997). DNA
indices (De Angelis et al, 1993, 1995, 1997), S phase fractions (De
Angelis et al, 1997) and apoptotic indices (AI; De Angelis et al,
1998), were determined previously for many of the tumours in this
series.
Statistical analyses
T-tests or Mann–Whitney two-tailed tests were used to check for
significant differences between two data groups for a specific
Table 2 Associations of chromosomal aberrations with gender, Dukes’ stage, tumour S phase fraction (SPF), apoptotic index (AI), TP53 and K-ras genotypes
Chromosome Chromosomal Minimal region Association with Association with Association Association Association with Association with
altered arm altered of involvement gender Dukes’ stage with SPF with AI TP53 genotype K-ras genotype
(No. detected) (No. detected) (No. detected) (P-value) (P-value) (P-value) (P-value) (P-value) (P-value)
1 (16) –1p (12) 1p21–31.1 (12) 0.72 0.30 0.76 1.00 0.48 0.46
4 (21) –4q (16) 1.00 0.21 0.26 0.05 0.10 0.31
5 (18) +5p (6) 0.65 0.18 0.38 0.66 0.40 0.16
–5q (12) 5q14–32 (12) 0.72 1.00 0.46 0.62 0.72 1.00
6 (14) –6q (9) 6q15–23 (9) 0.70 0.13 0.25 1.00 0.12 0.11
7 (15) +7p (15) 0.09 0.20 0.18 1.00 0.18 0.74
8 (30) –8p (12) 8p21.1-ter (12) 0.28 1.00 0.34 0.62 0.06 0.50
+8q (16) 8q23–24 (15) 0.52 1.00 0.81 1.00 0.04 0.10
13 (21) +13q (20) 13q32-ter (18) 0.33 0.53 0.65 0.69 0.10 1.00
15 (12) –15q (12) 15qcen-22 (11) 0.29 1.00 0.09 0.68 0.45 0.70
17 (17) –17p (10) 17p12–13 (10) 0.46 0.48 0.38 1.00 0.12 1.00
+17q (7) 17q21-ter (6) 1.00 0.09 0.31 NE 0.40 0.43
18 (23) –18q (23) 18qcen-21 (22) 0.01 0.13 0.77 0.71 0.02 0.20
20 (33) +20q (30) 20q13 (30) 0.09 0.54 0.03 0.44 0.08 0.74
X (20) +Xq (16) 0.05 0.52 0.39 0.03 1.00 1.00
Significant and marginally-significant associations observed were with male gender, Dukes’ C/D, high SPF, low AI, TP53 and K-ras mutations. One exception:
gain of Xq was associated with high AI. NE = not evaluable.Chromosomal gains and losses in colorectal tumours 531
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parameter. Fisher’s exact two-tailed 2 ´ 2 contingency test was
used to check for associations between any two parameters, and
Pearson or Spearman correlation analysis was used to check for
the degree of covariation between two variables. All statistical
testing was performed using Prism software (GraphPad Software,
San Diego, CA, USA). P-values  ≤0.05 were considered to be
significant. In some instances with Fisher’s exact test, the program
reported marginally-significant associations (P-values ranging
from 0.06 to 0.15).
RESULTS
Overview of genetic aberrations in colorectal
carcinomas detected by CGH
The CGH results for 45 colorectal carcinomas are summarized in
Figure 1 and Table 1. Chromosomal gains and losses are reported as
recurrent aberrations if they were seen in at least five or more cases
(> 10%) of 45 analysed. Four tumours had no detectable chromo-
somal aberrations. The median number of aberrations per tumour
was 7.0 (range 0–19); the numbers of aberrations per tumour were
distributed bimodally (Figure 2), with a natural cut-off at 6.0. The
median number of gains per tumour was 3.0, as was the median
number of losses. The number of gains per tumour correlated with
the number of losses (r = 0.58, P < 0.0001). Gains of 20q (in 67% of
tumours) and 13q (45%), and losses of 18q (49%) and 4q (36%)
were the most frequent aberrations. Gains of 5p (13%), 6p (11%), 7p
(33%), 8q (33%), 17q (16%), 19q (11%) and Xq (36%), and losses
of 1p (27%), 3p (11%), 5q (27%), 6q (20%), 8p (27%), 9p (16%),
10q (11%), 15q (27%) and 17p (22%), were other recurrent aberra-
tions. High-level gains (green to red ratio profiles >1.5) were seen
only on chromosomes/chromosome arms 8q, 13q, 20 and X. The
minimal regions of involvement (defined by a minimum of three
tumours) for recurrent aberrations occurring in > 13% of the
tumours are described in Table 2.
Thirty-one of 45 tumours were DNA aneuploid (DI > 1.0), and
14 tumours were DNA diploid (DI = 1.00). One aneuploid tumour
had two stemlines, one with a DI of 1.61 and one with a DI of 2.22.
DNA aneuploid tumours clearly had more chromosomal aberra-
tions than diploid tumours, with a median number of aberrations
per tumour of 9.0 (range 1–19) compared to 1.0 (range 0–12) in
DNA diploid tumours (P < 0.0001) (Figure 3). DNA aneuploid
and diploid tumours had similar types of chromosomal aberra-
tions. The four tumours with no detectable chromosomal aberra-
tions were all DNA diploid. Six aneuploid tumours were DNA
hyperdiploid (1.00 < DI < 1.30) and 25 were highly DNA aneu-
ploid (DI ³ 1.30); these two groups did not have significantly
different median numbers of aberrations per tumour (8.5 and 11.0
respectively;  P = 0.58). Four aneuploid tumours were near-
tetraploid/tetraploid (1.80 < DI ≤ 2.20), and these had a median
number of 3.0 aberrations per tumour (range 1–8).
Tumour genotypes and phenotypes
TP53 mutations were detected in 27 of 42 colorectal tumours
analysed for mutations, and 30 of 45 tumours were found to
express p53 by immunoblotting. K-ras mutations were detected in
18 of 40 tumours analysed for mutations in codons 12 and 13 of
the gene.
The distribution of S phase fractions for the tumour group was
Gaussian and ranged from 5.5% to 23.7%, with a mean (±s.d.) of
14.0% ±4.6. The distribution of apoptotic indices for the tumour
group was bimodal, and ranged from 0.0% to 5.4%, with a natural
cut-off at 1.0%. Tumours with < 1.0% apoptotic cells (18 of 30
analysed) were designated as having a low AI, and tumours with
³ 1.0% apoptotic cells (12 of 30) as those with a high AI for
the purposes of statistical analyses.
Associations of recurrent chromosomal aberrations
with clinicopathological parameters, tumour genotypes
and phenotypes
Table 2 summarizes the associations of the minimal regions of
involvement with patient gender, Dukes’ stage, tumour S phase
fraction, tumour apoptotic index, TP53 and K-ras genotypes.
Colorectal tumours from male patients had a median number of
aberrations per tumour of 7.5 (range 0–19), whereas tumours from
female patients had a median number of aberrations per tumour of
3.0 (range 0–13) (P = 0.099). Losses of 18q were detected in
significantly more tumours from males (63%) compared to
females (20%) (P = 0.01). Xq gains were also significantly associ-
ated with patient gender; 47% of tumours with Xq gain were
derived from male patients compared to 13% from female patients
(P = 0.05). Losses of/on chromosome X were detected in four
tumours, three of which were from females; the tumour from a
male with loss of X had a DNA index of 1.49.
Dukes’ C/D stage tumours (metastasizing) tended to have a
higher median number of aberrations per tumour compared to
Dukes’ B stage tumours (non-metastasizing), 10.0 (range 1–19)
versus 3.0 (range 0–14) (P = 0.065) respectively. The proportion
of detected aberrations which were designated as recurrent was
71% in Dukes’ C/D tumours, compared to 88% in Dukes’ B
tumours (median values; P = 0.437). There were no significant
associations of any recurrent chromosomal aberrations with
Dukes’ stage; however, Dukes’ C/D compared to Dukes’ B
tumours tended to have more losses of 6q (29% to 9%) and 18q
(62% to 35%) and more gains of 5p (19% to 4%) and 17q (24% to
4%) respectively.
Tumour S phase fractions were signficantly higher in colorectal
tumours with gains of chromosome arm 20q13 (mean of 15.2% ±4.5)
compared to tumours without 20q13 gain (mean of 12.0% ±4.0)
(P = 0.03). Correspondingly, tumour S phase fractions tended to
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be higher in tumours with 15qcen-22 loss than in tumours without
this loss (P = 0.09).
Low tumour AI were significantly associated with loss of chro-
mosome 4q, since 89% of tumours with 4q loss had low AI
compared to 48% of tumours without 4q loss (P = 0.05). High AI
were associated with Xq gain, since 75% of tumours with Xq gain
had high AI compared to 27% of tumours without (P = 0.03).
The median number of aberrations per tumour in tumours
without TP53 mutations was 2.0 (range 0–19), compared to a
median of 9.0 (range 0–19) in tumours with TP53 mutations (P =
0.002). However, the median number of aberrations per tumour
was not significantly different for p53-negative (3.0) compared to
p53-positive (7.5) tumours (P = 0.295). Gains of 8q23–24 were
significantly associated with TP53 mutations, since 48% of
tumours with TP53 mutations had these gains compared to only
13% of tumours with wild-type TP53 status (P = 0.04). Similarly,
67% of tumours with TP53 mutations had losses of 18qcen-21
compared to 27% of tumours without mutations (P = 0.02). There
were no significant associations of any chromosomal aberration
with TP53 phenotype.
The median numbers of chromosomal aberrations per tumour
were not significantly different between tumours with and without
K-ras mutations, 7.5 and 3.0 respectively (P = 0.253). There were
no significant associations demonstrated between any chromo-
somal aberration and K-ras genotype.
DISCUSSION
Our CGH results show that recurrent chromosomal aberrations in
colorectal tumours are manifested as whole or partial gains of chro-
mosomes/chromosome arms 5p, 6p, 7, 8q, 13q, 17q, 19q, 20q and
Xq, and whole or partial losses of chromosomes/chromosome arms
1p, 3p, 4, 5q, 6q, 8p, 9p, 10, 15q and 18. These results are for the
most part in agreement with those of Ried et al (1996; indirect
CGH), except that their study did not report any gains on
chromosome 19 or any losses on 6q, 10, or 15q. Additionally, the
frequency of individual chromosomal losses in their study gener-
ally tended to be lower than in ours. These discrepancies may be
due to the differences in detection sensitivity between the direct and
indirect CGH methods and to the differences in cut-off values used
when scoring chromosomal aberrations, or to the fact that they used
formalin-fixed archival material. Our results are also consistent
with the results of a karyotypic characterization of colorectal
tumours by Bardi et al (1995), who reported the same gains and
losses observed in the present study, but at lower frequencies for
several individual chromosomal aberrations.
Gains of 20q13 and 13q32-tel and losses of 18qcen-21 and 4q
were the most frequent aberrations seen in colorectal tumours.
Genes that map to these locations include an unknown oncogene at
20q13 (Tanner et al, 1994), the Smad2 tumour suppressor gene at
18q21 (Eppert et al, 1996) and the Smad4/DPC4 and DCC tumour
suppressor genes at 18q21.1 and 18q21.3 respectively (Hahn et al,
1996; Thiagalingam et al, 1996; Takagi et al, 1996; MacGrogan
et al, 1997). Colorectal tumours with gains of 20q13 had signifi-
cantly higher mean S phase fractions than those without,
suggesting that amplification of this gene locus may impart a
selective growth advantage by increasing the rate of proliferation.
Tumours with loss of 4q had lower apoptotic indices than those
without, which might indicate that loss of a gene on 4q results in a
suppression of apoptosis which again may be advantageous for the
overall net growth of a tumour. Other frequent gains seen were of
Xq, 8q23–24 and 7p. The c-myc (proto)oncogene maps to 8q24
and the EGFR gene is located on 7p. Other frequent losses seen
were of 1p21–31.1, 5q14–32, 8p2.1-ter, 15qcen-22, and 17p12–13.
The TP53 tumour suppressor gene maps to 17p13.1 and the APC
tumour suppressor gene to 5q21–22. Loss of heterozygosity (LOH)
of the TP53 gene is known to be implicated in colorectal carcino-
genesis, and it has been reported that about 20% of sporadic
colorectal carcinomas have LOH in the 5q21–22 region (Solomon
et al, 1987). Although we have not examined the present tumour
material for LOH at the APC locus, it is of interest to note that 27%
of the tumours in the present study show deletions of 5q14–32,
which covers the APC gene locus.
DNA diploid tumours generally had few to no aberrations
compared to aneuploid tumours; however, the types of aberrations
seen in both groups were similar. Four of 14 DNA diploid tumours
in the present study (9%) had no detectable aberrations by CGH,
which is in agreement with Ried et al (1996) who reported that
12% of colorectal tumours analysed by CGH had no detectable
copy number changes. There are several considerations to take
into account in a discussion of DNA diploidy in relation to CGH.
The first is that DNA diploid tumours may in fact have no gross
chromosomal aberrations, or that the aberrations (gains or losses)
are too small to be detected by CGH. Secondly, tumours with only
a few aberrations detected by CGH, e.g. gains or losses of one
large or two small chromosomes, will be measured as DNA
diploid even with high-resolution flow cytometry (Cusick et al,
1990). Finally, it is also possible that gains and losses in DNA
diploid tumours balance each other out, so that the net DNA
content measured by flow cytometry is ‘normal’, as has been
observed in DNA diploid non-Hodgkins lymphomas analysed by
CGH (T Stokke, submitted). We are confident that the percentage
of contaminating normal cells in DNA diploid tumour samples is
not a factor to be taken into consideration when no aberrations
were detected by CGH, since we have estimated the percentages of
both normal mucosal cells and leucocytes (30–40%) in the respec-
tive tumour sections and found them to be similar to those seen in
DNA aneuploid tumours. The fact that DNA diploid tumours have
so few aberrations compared to aneuploid tumours, even if the
actual aberrations are in themselves similar, suggests that genomic
instability and possible growth advantages in these tumours result
not from acquisition of gross chromosomal aberrations but rather
from selection for other (different) types of mutations. This idea is
supported by previous studies showing that DNA diploid tumours
exhibit microsatellite instability in contrast to DNA aneuploid
tumours (Lothe et al, 1993; Remvikos et al, 1995). Roughly
15–20% of sporadic colorectal carcinomas are microsatellite
unstable, and half of these are expected to be affected at the BAX
repeat locus ((G)8 tract of exon 3 of the BAX gene) (Rampino et al,
1997). The present tumour series was recently analysed for BAX
frameshift mutations at this locus (De Angelis et al, 1998), and
mutations were detected in three of 42 sporadic tumours analysed;
all three tumours were DNA diploid and localized to the right side
of the colon. We did not examine the present tumour series for
microsatellite instability at other loci. Furthermore, previous
studies have suggested that DNA aneuploid and diploid tumours
evolve along mostly separate genetic pathways, due to differences
between them concerning tumour localization in the colorectum
(Delattre et al, 1989; Offerhaus et al, 1992; Lothe et al, 1993), inci-
dence of TP53 mutations (Kikuchi-Yanoshita et al, 1992; Aaltonen
et al, 1993; Meling et al, 1993), and p53 phenotype (Remvikos et
al, 1990; Campo et al, 1991; De Angelis et al, 1993). However, the534 PM De Angelis et al
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end result is probably the same – that inactivation of specific
tumour suppressor pathways and/or activation of specific onco-
genic pathways are selected for despite the utilization of different
mechanisms (different aberration pathways) to achieve similar
goals. For example, the BAX gene, which promotes apoptosis, is
mutated in colorectal tumours with microsatellite instability which
typically do not have TP53 mutations (Rampino et al, 1997) and
which are DNA diploid (De Angelis et al, 1998). Colorectal
tumours with TP53 mutations and a high number of gross chromo-
somal aberrations (this work) produce mutant p53 proteins which
most likely cannot directly transactivate the BAX gene (Miyashita
and Reed, 1995). The apoptotic pathway in both types of tumours
is thus de-regulated (same selection pressure), but the mechanisms
whereby this is effected are different.
DNA hyperdiploid and highly DNA aneuploid tumours do not
appear to evolve along separate genetic pathways as was suggested
in an earlier study (Meling et al, 1993) since both the type and
number of gross chromosomal aberrations per tumour were not
significantly different. Finally, the numbers of aberrations in
tumours with and without K-ras mutations were not significantly
different, suggesting that selection for this mutation is not aberra-
tion pathway-specific.
The underlying mechanisms responsible for the genomic insta-
bility which results in the formation of aneuploid tumours are of
interest. De-regulation of G2/M checkpoint networks, cell divi-
sion/cytokinesis, and apoptotic pathways may lead to the forma-
tion and survival of cells with abnormal DNA content, and this
may be facilitated by loss of wild-type p53 function via TP53
mutation in some instances (for review see Shackney and Shankey,
1997). Several models for the generation of DNA aneuploid
tumours suggest that they are formed via tetraploidization of
diploid cancer cells followed by random chromosome loss
(Shackney et al, 1989) or tetraploidization of near-diploid cancer
cells (Giaretti, 1993). According to these hypotheses, DNA
tetraploid tumours might be expected to have none or few chromo-
somal aberrations by CGH, since they would have exactly double
the diploid or near-diploid chromosome complement. The DNA
tetraploid/near-tetraploid tumours in the present study had rela-
tively few aberrations per tumour compared to the aneuploid ones
(including both DNA hyperdiploid and highly DNA aneuploid
tumours). This is not consistent with tetraploid tumours evolving
gradually from diploidy through aneuploidy by sequentially
gaining single chromosomes or fragments. Our results suggest that
tetraploid tumours evolve by endoreduplication of a diploid or
near-diploid tumour cell. These may lose chromosomes to produce
DNA aneuploid tumours as is postulated by Shackney et al (1989),
but our results cannot elucidate this.
More tumours from males than females had gain of Xq and loss
of 18q. Losses of X (four cases) tended to be detected predomi-
nantly in tumours from females (three cases). The one tumour from
a male with loss of X had a triploid DNA content (DI of about 1.5),
which suggests that this tumour simply retained its original copy of
X. The results suggest that X may harbour both an oncogene and
a tumour suppressor gene(s), and that gene dosage effects of X
chromosome genes play a role in colorectal tumorigenesis.
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